Guangzhou Baiyunshan Pharmaceutical Group

The company was approved by the National Economic Reform Commission [0007] No. 139, and was exclusively initiated by Guangzhou Pharmaceutical Group Co., Ltd., and its eight Chinese medicine manufacturers and three pharmaceutical trading companies were reorganized. A joint stock limited company invested in the production of state-owned assets related to the production of operating assets. Mainly engaged in asset management, investment, development, financing, and engaged in the development and production of proprietary Chinese medicines, the production of biological products, health care drugs, health drinks, as well as the wholesale, retail and import and export of Chinese medicine, western medicine and medical equipment.